The advertised “Ozempic for $25” comes from the manufacturer savings card (Novo Nordisk). To qualify you need commercial insurance — through an employer or the ACA marketplace — that already covers Ozempic, plus a prescription for type 2 diabetes (its FDA-approved use). The card then reduces your copay to as little as $25 for a 1-month supply, with maximum savings of $150 per 1-month, $300 per 2-month, or $450 per 3-month fill.
Federal anti-kickback rules exclude government insurance: the card cannot be used with Medicare, Medicaid, VA or TRICARE. It also does not help if you are uninsured — there is currently no $25 cash route for brand Ozempic. Enroll on the official Ozempic savings page (ozempic.com) or by phone at 1-877-304-6855; pharmacies apply it like a secondary payer at the counter.
If you are uninsured or your plan excludes Ozempic, the practical alternatives are NovoCare self-pay semaglutide options (injectable Wegovy ~$349/month maintenance, $199 introductory; oral Wegovy from ~$149/month — different brand, same molecule class decisions belong to your prescriber) or compounded semaglutide via licensed telehealth (from about $69/month, not FDA-approved as a finished drug). Prices are estimates as of July 2026 and change without notice.